Origimm develops preventive and therapeutic products against the skin colonizing bacteria which can induce skin disease or infections at internal sites (e.g. infections associated with insertion of prosthetic implants or medical devices).

Our lead program is immune therapy against Propionibacterium acnes to treat acne vulgaris.
Additional programs include prophylactic immunization against Propionibacterium acnes and Staphylococcus epidermidis to prevent implant-associated infections.

continue reading…